1Unless stated otherwise, all notification data is AHPRA data.
The work of the Pharmacy Board of Australia built on initiatives from last year and was informed by an extensive program of stakeholder engagement.
The Board hosted the Pharmacy Prescribing Forum (the forum) in June which was attended by a wide range of stakeholders including consumers, pharmacists, regulators and government representatives. Participants explored the opportunities for pharmacist prescribing of Schedule 4 and Schedule 8 medicines that could be implemented and sustained as part of a broader range of health services to effectively meet the health needs of the community.
Following the forum, the Board published a report, which provided a summation of the issues raised and discussed by participants about the potential for pharmacists to prescribe through each of the three models of non-medical prescribing outlined in the Health Professionals Prescribing Pathway.
The Board published a discussion paper to progress the forum’s outcomes and a range of consultation questions to further explore:
Feedback from a broad range of participants expressed a range of views. During 2019/20, the Board will analyse the feedback and publish a report which is expected to advise the degree of support for prescribing by pharmacists and may include recommendations about any additional work required, including:
Following the development during 2018 of the Intern Year Blueprint (blueprint) by the Australian Pharmacy Council (APC) with funding from the Board, the next stage of the project started. The blueprint will become the framework used to determine future options for assessing pharmacy interns against the revised competency standards for pharmacists. The Board, in collaboration with the APC, formed the Intern Year Blueprint Implementation Working Group (the working group), to develop a strategy to determine the most appropriate and effective type of assessment for each competency from the range of choices described in the blueprint, and to identify the organisation with the prime responsibility to develop and administer the assessment. The working group will continue to meet during 2019/20 and engage with stakeholders.
The Board conducted the National Pharmacy Internship Experience Survey, a large-scale survey to investigate issues relevant to the quality of the intern training experience. Interns and preceptors who participated provided feedback on their own intern training experiences. The results of the survey were analysed and a report was prepared. A stakeholder engagement plan is being developed to guide future engagement and action during the next reporting period. The results of the survey are anticipated to guide policy development regarding future arrangements for supervision of interns and are also likely to provide useful insights to be taken into account in reviewing assessment processes for interns.
The Board developed an induction program for newly appointed Board members to complement National Scheme induction and governance training. Upon appointment by Ministers, seven new Board members were inducted. New members were also supported by an ongoing program of mentoring to facilitate their transition to their roles and effective participation at Board and committee meetings.
The Board, the APC and AHPRA signed a new five-year accreditation agreement starting 1 July 2019. The accreditation agreement is a contemporary framework designed to address key accreditation issues. The agreement also includes principles for funding and fee setting and new key performance indicators to track progress on priority issues.
I am pleased to present this report of the Board’s activities in this my first year as its Chair.
Mr Brett Simmonds, Chair